The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
COP1 (Constitutive Photomorphogenesis Protein 1, gene symbol COP1, also known as RFWD2) is a highly conserved E3 ubiquitin-protein ligase in Homo sapiens (UniProt Q8NHY2). It has a verified structure featuring four major domains: an N-terminal glycine/serine-rich domain, a RING finger domain (crucial for E2 enzyme binding), a central coiled-coil domain (required for dimerization and oligomerization), and a C-terminal WD40-repeat domain (responsible for substrate recognition and binding, especially through Val-Pro motifs) (wang2026cryoemstructureof pages 1-2, wang2026cryoemstructureof pages 2-3, wang2026cryoemstructureof pages 4-5).
COP1 catalyzes the transfer of ubiquitin from E2 enzymes to specific substrate proteins, marking them for proteasomal degradation. It can act as a standalone E3 ligase, but more commonly operates as the substrate receptor in the CRL4 E3 ubiquitin ligase complex (CRL4COP1/DET1), which includes CUL4, DDB1, DET1, DDA1, RBX1, and associated E2 enzymes (wang2026cryoemstructureof pages 1-2, wang2026cryoemstructureof pages 2-3).
COP1's E3 ligase activity is exerted through the RING finger domain, which recruits E2 ubiquitin-conjugating enzymes. Substrate selection is mediated by the WD40 domain, which recognizes a consensus VP (Val-Pro) degron motif present in many COP1 targets. COP1 also features two nuclear localization signals flanking the RING domain, supporting its functions within the nucleus (wang2026cryoemstructureof pages 1-2, wang2026cryoemstructureof pages 2-3).
Cryo-EM structures (Wang et al. 2026) have detailed the assembly of human COP1 within CUL4-based ligase complexes, highlighting conformational changes upon substrate engagement and identifying the dynamic states regulating substrate access (wang2026cryoemstructureof pages 1-2, wang2026cryoemstructureof pages 2-3, wang2026cryoemstructureof pages 4-5).
COP1 predominantly localizes to both the nucleus and cytoplasm, but at baseline is highly enriched at the nuclear envelope via interactions with the nuclear pore complex component TPR. In response to MAPK/ERK signaling inactivation, COP1 is rapidly released from the nuclear envelope into the nucleoplasm, where it mediates the degradation of nuclear protein substrates, such as transcription factors (ouyang2020erk12inactivationpromotes pages 1-3).
A comprehensive substrate table, summarizing human COP1 targets, their biological roles, and supporting citations, is included below:
| Substrate name | Substrate type/function | Biological process regulated by COP1-mediated turnover | Evidence source (citation information) | Year |
|---|---|---|---|---|
| p53 (TP53) | Tumor suppressor transcription factor | Stress responses, cell-cycle arrest, apoptosis, tumor suppression; COP1-mediated ubiquitination/degradation reduces p53 stability | First mammalian COP1 substrate discussed in structural review; p53 described as a COP1 target whose disruption stabilizes p53 (wang2026cryoemstructureof pages 2-3, hu2023structuralbasisof pages 1-3, grigoreva2024p53themultifaceted pages 1-2) | 2023, 2024, 2026 |
| c-JUN | AP-1 family transcription factor | Cell proliferation, differentiation, survival; rapidly degraded after ERK1/2 inactivation via COP1 | CRL4^COP1/DET1 and COP1-dependent c-JUN degradation described in mechanistic and structural studies (wang2026cryoemstructureof pages 2-3, ouyang2020erk12inactivationpromotes pages 1-3) | 2020, 2026 |
| ETV1 | ETS family transcription factor | Developmental and oncogenic transcriptional programs; COP1 promotes degradation | Listed among established COP1 substrates in mammalian cells (ndoja2020ubiquitinligasecop1 pages 1-3, wang2026cryoemstructureof pages 2-3) | 2020, 2026 |
| ETV4 | ETS family transcription factor | Mitogen-responsive transcription, proliferation, cancer-associated programs; COP1-dependent degradation, especially after ERK1/2 inactivation | Listed as CRL4^COP1/DET1 substrate and experimentally restored by COP1 knockdown (ndoja2020ubiquitinligasecop1 pages 1-3, ouyang2020erk12inactivationpromotes pages 1-3) | 2020 |
| ETV5 | ETS family transcription factor | Mitogen-responsive transcription, proliferation, cancer-associated programs; COP1-dependent degradation | Listed as CRL4^COP1/DET1 substrate and experimentally restored by COP1 knockdown (ndoja2020ubiquitinligasecop1 pages 1-3, ouyang2020erk12inactivationpromotes pages 1-3) | 2020 |
| ETS1 | ETS family transcription factor | Immune/developmental transcription programs and oncogenic signaling; COP1-mediated turnover | Named among COP1 substrates in review/mechanistic discussion (ndoja2020ubiquitinligasecop1 pages 1-3, ducker2021ubiquitinmediatedcontrolof pages 1-2) | 2020, 2021 |
| ETS2 | ETS family transcription factor | Developmental signaling and oncogenic transcriptional regulation; recognized by COP1 WD40 substrate-binding interface | Named among COP1 substrates and used as substrate in structural work (ndoja2020ubiquitinligasecop1 pages 1-3, wang2026cryoemstructureof pages 1-2, wang2026cryoemstructureof pages 2-3) | 2020, 2026 |
| c/EBPβ (CEBPB) | CCAAT/enhancer-binding transcription factor | Microglial inflammatory state, neuroinflammation, complement-dependent neurotoxicity; COP1 suppresses its accumulation | Direct biochemical and functional evidence showing COP1 promotes proteasomal degradation of c/EBPβ (ndoja2020ubiquitinligasecop1 pages 1-3, ndoja2020ubiquitinligasecop1 pages 3-4) | 2020 |
| c/EBPα (CEBPA) | CCAAT/enhancer-binding transcription factor | Myeloid differentiation and growth control; known COP1 substrate via adaptor-mediated recruitment | Listed as established COP1 substrate in mammalian cells (ndoja2020ubiquitinligasecop1 pages 1-3, wang2026cryoemstructureof pages 4-5) | 2020, 2026 |
| UTX (KDM6A) | H3K27me2/3 histone demethylase; tumor suppressor | Chromatin regulation and colorectal tumor suppression; COP1-containing CRL4 complex promotes degradation, lowering UTX and favoring CRC progression | CRC study identifies CUL4B-DDB1-COP1 as functional E3 ligase for UTX degradation (luo2023cul4bddb1cop1mediatedutxdownregulation pages 1-2) | 2023 |
| P57Kip2 (CDKN1C) | Cyclin-dependent kinase inhibitor | Trophoblast cell-cycle exit and syncytiotrophoblast fusion; COP1-mediated degradation inhibits trophoblast fusion | STK40-dependent recruitment to COP1 reported in placental/trophoblast study (wang2026cryoemstructureof pages 1-2) | 2024 |
| ACSL4 | Acyl-CoA synthetase involved in lipid metabolism and ferroptosis sensitivity | Ferroptosis control in renal cell carcinoma; COP1-mediated K48-linked ubiquitination reduces ACSL4 and suppresses ferroptosis | RCC study identifies ACSL4 as direct COP1 substrate (wang2026cryoemstructureof pages 1-2) | 2025 |
| LUZP1 | Leucine zipper protein 1; cytoskeletal/signaling-associated protein | Colorectal cancer liver metastasis and oxaliplatin resistance; COP1-mediated degradation activates downstream MYL9 phosphorylation and EMT/JAK2-STAT3 signaling | Multi-omics organoid study identifies COP1-LUZP1 axis (wang2026cryoemstructureof pages 1-2) | 2026 |
| c/EBP family/Tribbles-recruited substrates (general) | Transcription factors recruited by pseudokinase adaptors such as STK40/TRIB proteins | Signal-dependent repression of differentiation or inflammatory programs through adaptor-assisted COP1 targeting | Structural and functional studies indicate COP1 substrate recognition via WD40 domain and adaptor-assisted recruitment (wang2026cryoemstructureof pages 2-3, ndoja2020ubiquitinligasecop1 pages 3-4, wang2026cryoemstructureof pages 4-5) | 2020, 2026 |
Table: This table summarizes human COP1/RFWD2 substrates identified or discussed in the collected literature, including their functions and the biological processes affected by COP1-mediated degradation. It is useful for organizing the functional annotation of COP1 around its substrate repertoire and pathway roles.
COP1 regulates a spectrum of substrates that control critical processes, including:
- Tumor suppression and cell cycle regulation: p53 (TP53), P57Kip2, UTX (KDM6A).
- Transcriptional programs and oncogenesis: c-Jun (AP-1), ETS family (ETV1, ETV4, ETV5, ETS1, ETS2), c/EBPα, c/EBPβ.
- Metabolism and stress responses: ACSL4 (ferroptosis, lipid metabolism), LUZP1 (EMT, chemoresistance), CDH18 (PI3K/AKT pathway).
COP1 often acts as a signal transducer, quickly converting extracellular signals (such as MAPK/ERK inactivation and DNA damage) into rapid changes in substrate stability. For example, DNA damage inactivates COP1 via ATM-mediated phosphorylation and subsequent autoubiquitination (wang2026cryoemstructureof pages 2-3, ouyang2020erk12inactivationpromotes pages 1-3).
Recent high-impact studies (2023-2026):
- 2026 cryo-EM structure of human COP1-DET1 ligase complex, revealing new mechanistic insights (Nature Communications, Wang et al., 2026).
- 2025-2026: COP1's regulation of ACSL4 in renal cell carcinoma (Frontiers in Oncology), and LUZP1 in colorectal cancer metastasis (Exp Hematol Oncol).
- 2023: COP1-mediated UTX downregulation in colorectal cancer (Exp Hematol Oncol).
- 2024: COP1 and c/EBPβ in Alzheimer's pathobiology (CNS Neurosci Ther).
- 2020-2023: Cross-disease evidence for COP1 in neuroinflammation, cell differentiation, and cell cycle regulation (ndoja2020ubiquitinligasecop1 pages 1-3, ndoja2020ubiquitinligasecop1 pages 3-4).
Leading reviews and mechanistic studies (2021-2026) repeatedly highlight COP1/RFWD2 as a central, multi-functional E3 ubiquitin ligase coordinating cellular fate through fast posttranslational control of transcription factors and chromatin regulators. Human molecular genetics, biochemistry, and translational disease research communities consider COP1-mediated protein degradation as a crucial lever in tumorigenesis, neuroinflammation, and development (ndoja2020ubiquitinligasecop1 pages 1-3, wang2026cryoemstructureof pages 2-3, ducker2021ubiquitinmediatedcontrolof pages 1-2, hu2023structuralbasisof pages 1-3, ndoja2020ubiquitinligasecop1 pages 3-4, grigoreva2024p53themultifaceted pages 1-2, wang2026cryoemstructureof pages 4-5, ouyang2020erk12inactivationpromotes pages 1-3).
Human COP1 (RFWD2; Q8NHY2) is a modular, multi-domain E3 ubiquitin ligase that operates primarily at the nuclear envelope and within the nucleus to regulate protein stability of critical transcription factors, tumor suppressors, chromatin enzymes, and metabolic regulators. It acts through specific VP-motif substrate interactions and rapidly translates signaling inputs into graded or switch-like degradation of select protein targets, orchestrating numerous physiological and pathological outcomes. Its inclusion in CUL4 CRL4COP1/DET1 complexes expands its substrate repertoire and regulatory scope.
COP1 research is expanding rapidly, with frequent new substrate discoveries, disease links, and high-resolution structural elucidations. This keeps its annotation highly dynamic and underscores its translational relevance.
Key references include:
- Wang et al., Nature Communications 2026 [https://doi.org/10.1038/s41467-026-68375-7] (wang2026cryoemstructureof pages 1-2, wang2026cryoemstructureof pages 2-3, wang2026cryoemstructureof pages 4-5)
- Ndoja et al., Cell 2020 [https://doi.org/10.1016/j.cell.2020.07.011] (ndoja2020ubiquitinligasecop1 pages 1-3, ndoja2020ubiquitinligasecop1 pages 3-4)
- Ducker & Shaw, IJMS 2021 [https://doi.org/10.3390/ijms22105119] (ducker2021ubiquitinmediatedcontrolof pages 1-2)
- Luo et al., Exp Hematol Oncol 2023 [https://doi.org/10.1186/s40164-023-00440-z] (luo2023cul4bddb1cop1mediatedutxdownregulation pages 1-2)
- Ouyang et al., PNAS 2020 [https://doi.org/10.1073/pnas.1913698117] (ouyang2020erk12inactivationpromotes pages 1-3)
- Hu et al., Communications Biology 2023 [https://doi.org/10.1038/s42003-023-04458-1] (hu2023structuralbasisof pages 1-3)
- Grigoreva et al., Pharmaceuticals 2024 [https://doi.org/10.3390/ph17121682] (grigoreva2024p53themultifaceted pages 1-2)
References
(wang2026cryoemstructureof pages 1-2): Shan Wang, Fei Teng, Goran Stjepanovic, Feng Rao, and Ming-Yuan Su. Cryo-em structure of the human cop1-det1 ubiquitin ligase complex. Nature Communications, Jan 2026. URL: https://doi.org/10.1038/s41467-026-68375-7, doi:10.1038/s41467-026-68375-7. This article has 2 citations and is from a highest quality peer-reviewed journal.
(wang2026cryoemstructureof pages 2-3): Shan Wang, Fei Teng, Goran Stjepanovic, Feng Rao, and Ming-Yuan Su. Cryo-em structure of the human cop1-det1 ubiquitin ligase complex. Nature Communications, Jan 2026. URL: https://doi.org/10.1038/s41467-026-68375-7, doi:10.1038/s41467-026-68375-7. This article has 2 citations and is from a highest quality peer-reviewed journal.
(wang2026cryoemstructureof pages 4-5): Shan Wang, Fei Teng, Goran Stjepanovic, Feng Rao, and Ming-Yuan Su. Cryo-em structure of the human cop1-det1 ubiquitin ligase complex. Nature Communications, Jan 2026. URL: https://doi.org/10.1038/s41467-026-68375-7, doi:10.1038/s41467-026-68375-7. This article has 2 citations and is from a highest quality peer-reviewed journal.
(ouyang2020erk12inactivationpromotes pages 1-3): Weiming Ouyang, Pengfei Guo, Kazuyo Takeda, Qiong Fu, Hui Fang, and David M. Frucht. Erk1/2 inactivation promotes a rapid redistribution of cop1 and degradation of cop1 substrates. Proceedings of the National Academy of Sciences, 117:4078-4087, Feb 2020. URL: https://doi.org/10.1073/pnas.1913698117, doi:10.1073/pnas.1913698117. This article has 16 citations and is from a highest quality peer-reviewed journal.
(hu2023structuralbasisof pages 1-3): Jianjian Hu, Wenxue Jiang, Jiaqi Zuo, Dujuan Shi, Xiaoqi Chen, Xiao Yang, Wenhui Zhang, Lixin Ma, Zhu Liu, and Qiong Xing. Structural basis of bacterial effector protein azurin targeting tumor suppressor p53 and inhibiting its ubiquitination. Communications Biology, Jan 2023. URL: https://doi.org/10.1038/s42003-023-04458-1, doi:10.1038/s42003-023-04458-1. This article has 22 citations and is from a peer-reviewed journal.
(grigoreva2024p53themultifaceted pages 1-2): Tatiana A. Grigoreva, Angelina A. Romanova, Vyacheslav G. Tribulovich, Nikolay B. Pestov, Ruslan A. Oganov, Diana K. Kovaleva, Tatyana V. Korneenko, and Nickolai A. Barlev. P53: the multifaceted roles of covalent modifications in cancer. Pharmaceuticals, 17:1682, Dec 2024. URL: https://doi.org/10.3390/ph17121682, doi:10.3390/ph17121682. This article has 14 citations.
(ndoja2020ubiquitinligasecop1 pages 1-3): Ada Ndoja, Rohit Reja, Seung-Hye Lee, Joshua D. Webster, Hai Ngu, Christopher M. Rose, Donald S. Kirkpatrick, Zora Modrusan, Ying-Jiun Jasmine Chen, Debra L. Dugger, Vineela Gandham, Luke Xie, Kim Newton, and Vishva M. Dixit. Ubiquitin ligase cop1 suppresses neuroinflammation by degrading c/ebpβ in microglia. Cell, 182:1156-1169.e12, Sep 2020. URL: https://doi.org/10.1016/j.cell.2020.07.011, doi:10.1016/j.cell.2020.07.011. This article has 177 citations and is from a highest quality peer-reviewed journal.
(ducker2021ubiquitinmediatedcontrolof pages 1-2): Charles Ducker and Peter E. Shaw. Ubiquitin-mediated control of ets transcription factors: roles in cancer and development. International Journal of Molecular Sciences, 22:5119, May 2021. URL: https://doi.org/10.3390/ijms22105119, doi:10.3390/ijms22105119. This article has 16 citations.
(ndoja2020ubiquitinligasecop1 pages 3-4): Ada Ndoja, Rohit Reja, Seung-Hye Lee, Joshua D. Webster, Hai Ngu, Christopher M. Rose, Donald S. Kirkpatrick, Zora Modrusan, Ying-Jiun Jasmine Chen, Debra L. Dugger, Vineela Gandham, Luke Xie, Kim Newton, and Vishva M. Dixit. Ubiquitin ligase cop1 suppresses neuroinflammation by degrading c/ebpβ in microglia. Cell, 182:1156-1169.e12, Sep 2020. URL: https://doi.org/10.1016/j.cell.2020.07.011, doi:10.1016/j.cell.2020.07.011. This article has 177 citations and is from a highest quality peer-reviewed journal.
(luo2023cul4bddb1cop1mediatedutxdownregulation pages 1-2): Dakui Luo, Min Chen, Qingguo Li, Kangjunjie Wang, Kaihua Wang, Junqiang Li, Guoxiang Fu, Zezhi Shan, Qi Liu, Yufei Yang, Lei Liang, Yanlei Ma, Yi Qin, Jun Qin, Daming Gao, and Xinxiang Li. Cul4b-ddb1-cop1-mediated utx downregulation promotes colorectal cancer progression. Experimental Hematology & Oncology, Sep 2023. URL: https://doi.org/10.1186/s40164-023-00440-z, doi:10.1186/s40164-023-00440-z. This article has 31 citations and is from a peer-reviewed journal.